Efficacy of Anifrolumab in Systemic Lupus Erythematosus by Overall and Organ-Specific SLEDAI-2K Improvements: Results from the Randomized, Placebo-Controlled Phase 3 Long-Term Extension Study

被引：0

作者：

Furie, Richard A. ^{[1
]}

Kalunian, Kenneth ^{[2
]}

Morand, Eric ^{[3
]}

Bruce, Ian ^{[4
]}

Manzi, Susan ^{[5
]}

Tanaka, Yoshiya ^{[6
]}

Withrop, Kevin ^{[7
]}

Hupka, Ihor ^{[8
]}

Hultquist, Micki ^{[9
]}

Tummala, Raj ^{[9
]}

Abreu, Gabriel ^{[10
]}

Lindholm, Catharina ^{[10
]}

Al-Mossawi, Hussein ^{[11
]}

机构：

[1] Donald & Barbara Zucker Sch Med Hofstra Northwell, Great Neck, NY USA

[2] Univ Calif San Diego, La Jolla, CA USA

[3] Monash Univ, Ctr Inflammatory Dis, Melbourne, Australia

[4] Univ Manchester, Manchester, Lancs, England

[5] Allegheny Hlth Network, Autoimmun Inst, Lupus Ctr Excellence, Pittsburgh, PA USA

[6] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka, Japan

[7] Oregon Hlth & Sci Univ, Sch Med & Publ Hlth, Portland, OR USA

[8] AstraZeneca, BioPharmaceut R&D, Warsaw, Poland

[9] AstraZeneca, BioPharmaceut R&D, Gaithersburg, MD USA

[10] AstraZeneca, BioPharmaceut R&D, Gothenburg, Sweden

[11] AstraZeneca, BioPharmaceut R&D, Cambridge, England

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0597

引用

页码：1184 / 1186

页数：3

共 50 条

[1] A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
Kalunian, Kenneth C.
Furie, Richard
Morand, Eric F.
Bruce, Ian N.
Manzi, Susan
Tanaka, Yoshiya
Winthrop, Kevin
Hupka, Ihor
Zhang, Lijin Jinny
Werther, Shanti
Abreu, Gabriel
Hultquist, Micki
Tummala, Raj
Lindholm, Catharina
Al-Mossawi, Hussein
[J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 (02) : 253 - 265
[2] LABORATORY MARKER IMPROVEMENTS FOLLOWING LONG-TERM TREATMENT WITH ANIFROLUMAB IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE PLACEBO-CONTROLLED TULIP EXTENSION STUDY
Vital, E.
Amoura, Z.
Kalunian, K.
Bruce, I. N.
Tanaka, Y.
Manzi, S.
Hupka, I.
Yavuz, S.
Abreu, G.
Lindholm, C.
Al-Mossawi, H.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1451 - 1452
[3] PERFORMANCE OF SLEDAI-2K RESPONDER INDEX-50 IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL WITH USTEKINUMAB (UST) IN SYSTEMIC LUPUS ERYTHEMATOSUS
Touma, Zahi
Gladman, Dafna
Fei, Kaiyin
Gregan, Irene
Zazzetti, Federico
Gordon, Robert
Lo, Kim Hung
Rose, Shawn
Urowitz, Murray
[J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S39 - S39
[4] Long-term Safety and Efficacy of Anifrolumab in Adult Patients with Systemic Lupus Erythematosus: A Multicenter, Randomized, Double-blind, Placebo-controlled 3-year TULIP Extension Study
Kalunian, Kenneth C.
Furie, Richard A.
Morand, Eric F.
Bruce, Ian N.
Manzi, Susan
Tanaka, Yoshiya
Winthrop, Kevin
Abreu, Gabriel
Hupka, Ihor
Zhang, Lijin
Werther, Shanti
Hultquist, Micki
Tummala, Raj
Lindholm, Catharina
[J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3285 - 3288
[5] SLEDAI-2K Responder Index-50 Is Effective in Demonstrating Partial Response in a Phase 2, Randomized Placebo-Controlled Study of Ustekinumab in Patients with Active Systemic Lupus Erythematosus
Touma, Zahi
Urowitz, Murray
Gladman, Dafna D.
Wagner, Carrie
Zhou, Bei
Gordon, Robert
Hsu, Benjamin
Chevrier, Marc
Rose, Shawn
[J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
[6] Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study
Chatham, W. Winn
Furie, Richard
Saxena, Amit
Brohawn, Philip
Schwetje, Erik
Abreu, Gabriel
Tummala, Raj
[J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 (05) : 837 - 847
[7] LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT IN THE PHASE 3 PLACEBO-CONTROLLED TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB
Morand, E. F.
Van Vollenhoven, R.
Furie, R.
Kalunian, K.
Yavuz, S.
Abreu, G.
Lindholm, C.
Al-Mossawi, H.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 33 - 34
[8] A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus
Chatham, W. Winn
Furie, Richard
Saxena, Amit
Brohawn, Philip
Schwetje, Erik
Abreu, Gabriel
Tummala, Raj
[J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
[9] Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial
Tanaka, Yoshiya
Bass, Damon
Chu, Myron
Egginton, Sally
Ji, Beulah
Roth, David
[J]. MODERN RHEUMATOLOGY, 2020, 30 (02) : 313 - 320
[10] Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Wallace, Daniel J.
Furie, Richard
Tanaka, Yoshiya
Kalunian, Kenneth C.
Mosca, Marta
Petri, Michelle
Dorner, Thomas
Cardiel, Mario H.
Bruce, Ian N.
Gomez, Elisa
DeLozier, Amy M.
Janes, Jonathan
Linnik, Matthew D.
de Bono, Stephanie
Silk, Maria E.
Hoffman, Robert W.
[J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70

← 1 2 3 4 5 →